FDA grants priority review to Pfizer TALZENNA-XTANDI combo in metastatic prostate cancer
PFE•TALAPRO-3 study results
TALAPRO-3 data showed a 52% reduction in risk of radiographic progression or death versus placebo with XTANDI.
FDA priority review for TALZENNA with XTANDI
The FDA accepted Pfizer’s priority review for TALZENNA with XTANDI in HRR-altered metastatic castration-sensitive prostate cancer.
The PDUFA action date is set for Q4 2026. Approval would expand use from metastatic castration-resistant disease.
Related News
Dexcom Announced As First Participant Selected For FDA's Tempo Digital Health Devices Pilot Program
DXCM•
Delek Logistics Partners, LP Increases Quarterly Cash Distribution To $1.135 Per Common Limited Partner Unit
DKL•
